Wissenschaftl. Titel | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD |
Erkrankung |
Herz und Kreislauf:
sonstige
|
weitere Prüfzentren | |
Kurzprotokoll | Kurzprotokoll |
Links | Zu den Ein- und Ausschlusskriterien |
erstellt 30.04.2024 Admin02
geändert 27.11.2024 Admin07